PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 13, 2026SHILAP Revista de lepidopterologíaOpen Access

Epigenetic inhibition of class I histone deacetylases by MS-275 attenuates diabetic skeletal muscle atrophy via Akt/ARK5–FoxO and myostatin–Smad signaling

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYoungho SonHBHye-Eun ByeonSCSung-E Choi

Discussion

Loading...

Member takes

Overview

Notable findings show MS-275 improves muscle mass in diabetic models, indicating a novel therapeutic approach.

Key Points

  • This research aims to explore the role of class I histone deacetylase inhibition in diabetic muscle atrophy.
  • Used male db/db mice as a diabetes model
  • Administered MS-275 for 4 weeks
  • Assessed skeletal muscle mass via MRI and histological analysis
  • Analyzed inflammatory responses and signaling pathways using multiple biochemical assays
  • MS-275 treatment significantly increased skeletal muscle mass and fiber size
  • Reduced levels of macrophage infiltration and pro-inflammatory cytokines
  • Decreased circulating myostatin levels and inhibited Smad2/3 signaling
  • Restored phosphorylation of Akt and ARK5, promoting FoxO1/3 phosphorylation
  • Lowered expression of muscle-specific E3 ubiquitin ligases MuRF1 and atrogin-1

Cite This Study

Son et al. (2026) studied this question.

synapsesocial.com/papers/69b3aaa802a1e69014ccb688https://doi.org/10.3389/fendo.2026.1788603
View Full Paper
Ask AI
Bookmark
Share